Palifermin vs BMP-7
Head-to-head comparison of Palifermin (Recombinant Human Keratinocyte Growth Factor (KGF, FGF7)) and BMP-7 (Recombinant Human Bone Morphogenetic Protein-7) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Palifermin | BMP-7 |
|---|---|---|
| Category | Recovery & Healing | Recovery & Healing |
| Full Name | Recombinant Human Keratinocyte Growth Factor (KGF, FGF7) | Recombinant Human Bone Morphogenetic Protein-7 |
| Molecular Weight | 16.3 kDa | 35000 Da |
| Half-Life | 4–6 hours | short, localized exposure |
| Amino Acids | 140 | 139 |
| Typical Dose | 60 µg/kg/day | procedure-dependent local implant |
| Route | Intravenous | Local/Implant |
| Purity | ≥98% | ≥98% |
| Studies Count | 250 | 700 |
| Research Status | Clinical | Clinical |
Palifermin Benefits
- ✓epithelial protection
- ✓mucosal regeneration
- ✓barrier restoration
- ✓reduced inflammatory injury
BMP-7 Benefits
- ✓supports bone formation
- ✓may aid nonunion repair
- ✓promotes connective tissue regeneration
- ✓helps scaffold integration
Palifermin Dosing
IV 60 µg/kg/day for 3 days before and 3 days after insult|research protocols vary|short courses only
BMP-7 Dosing
local implantation|single procedural exposure|research or device-specific delivery
Palifermin Side Effects
- ⚠rash
- ⚠taste changes
- ⚠edema
- ⚠arthralgia
BMP-7 Side Effects
- ⚠local swelling
- ⚠inflammation
- ⚠ectopic mineralization
Research Overview
Palifermin
Palifermin is clinically established for mucosal protection and has been studied for epithelial repair in other tissues. The strongest evidence is for epithelial resilience and regeneration rather than direct dermal remodeling.
BMP-7
rhBMP-7 has a long history in preclinical and clinical literature for bone repair, particularly in challenging healing environments. Its cartilage-related research is less mature than BMP-2 but still relevant to musculoskeletal regeneration.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.